Intervention: Deferasirox
Trial phase: Phase 2
ATC code: V03AC03
SMILES: O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Deferasirox (Novartis Pharma): Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
Eligibility criteria:
Inclusion Criteria:

MDS of subtype RA, RARS, RCMD, RCMD-RS (i.e. lower risk)
RAEB I allowed, if clinically stable for > 3 months
5q-minus syndrome allowed, if lenalidomide unsuccessful or unavailable at the time of inclusion
IPSS score < intermediate-1
transfusion dependent or Hb < 10,5 g/dl
History of less than 20 units of red blood cell transfusions or 100mL/kg of prepacked red blood cells (PRBCs), except for transfusions for acute bleeding
Serum ferritin > 300 µg/l and < 1500 μg/l. This level should have been verified at least at two occasions within 3 months. Samples must be obtained in the absence of concomitant severe infection
no indication for EPO (due to high endogenous EPO levels) or EPO without benefit in the past
no indication and/or no plans for cytostatic drugs
no previous exposure to cytostatic drugs, thalidomide, lenalidomide, G-CSF or EPO or exposure to any of these drugs has been terminated since > 8 weeks (4 weeks for G-CSF).
no indication and/or no plans for stem cell transplantation
stable or worsening cytopenia during the past 8 weeks. If in doubt, extend screening period to >= 8 weeks
Patients of either gender and age > 18 years
Life expectancy > 12 months
Females of childbearing potential must use double-barrier contraception (for example orale contraception and condom).
Mental ability of the patient to understand explications concerning the study and to understand and follow instructions of the investigating physician
Written informed consent by the patient

Exclusion Criteria:

Treatment with deferasirox or other chelation therapy for periods > 4 weeks before study start
Patients with intolerance to Deferasirox
Patients with a concomitant second malignant disease, possibly interfering with life expectancy
Patients with mean levels of alanine aminotransferase (ALT) > 5x ULN
Patients with uncontrolled systemic hypertension
Patients with serum creatinine > 1.5x the upper limit of normal (ULN) or a creatinine clearance < 60 ml/min according to the MDRD formula (Levey 2005)
History of nephrotic syndrome
Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment
Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing study treatment
Patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drug within the past 7 days
Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:
history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase;
history of urinary obstruction or difficulty in voiding
History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative
History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by laboratory assays conducted during the screening period
Patients with active uncontrolled infectious disease
Pregnancy or breast feeding
QT > 470 msec on screening ECG
Patients with a history of Torsades de Pointes